The global COVID-19 In-Vitro Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for COVID-19 In-Vitro Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 In-Vitro Diagnostics.
Report Scope
The COVID-19 In-Vitro Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global COVID-19 In-Vitro Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the COVID-19 In-Vitro Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Cellex
Abbott
Roche
BioMedomics
BD
Henry Schein
Safecare Bio-Tech
Mayo Clinic Laboratories
Chembio Diagnostics
Mount Sinai Laboratory
Ortho Clinical Diagnostics
Zhejiang Orient Gene Biotech
Innovita Biological Technology
Guangzhou Wondfo Biotech
Guangdong Hecin-Scientific
Dynamiker Biotechnology (Tianjin)
ADVAITE
Segment by Type
Rapid Diagnostic Test (RDT)
Enzyme Linked Immunosorbent Assay (ELISA)
Neutralization Assay
Segment by Application
麻豆原创
Hospital
Clinical
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COVID-19 In-Vitro Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Rapid Diagnostic Test (RDT)
1.2.3 Enzyme Linked Immunosorbent Assay (ELISA)
1.2.4 Neutralization Assay
1.3 麻豆原创 by Application
1.3.1 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 麻豆原创
1.3.3 Hospital
1.3.4 Clinical
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Perspective (2019-2030)
2.2 COVID-19 In-Vitro Diagnostics Growth Trends by Region
2.2.1 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 COVID-19 In-Vitro Diagnostics Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 COVID-19 In-Vitro Diagnostics Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 COVID-19 In-Vitro Diagnostics 麻豆原创 Dynamics
2.3.1 COVID-19 In-Vitro Diagnostics Industry Trends
2.3.2 COVID-19 In-Vitro Diagnostics 麻豆原创 Drivers
2.3.3 COVID-19 In-Vitro Diagnostics 麻豆原创 Challenges
2.3.4 COVID-19 In-Vitro Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 In-Vitro Diagnostics Players by Revenue
3.1.1 Global Top COVID-19 In-Vitro Diagnostics Players by Revenue (2019-2024)
3.1.2 Global COVID-19 In-Vitro Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 In-Vitro Diagnostics Revenue
3.4 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global COVID-19 In-Vitro Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 In-Vitro Diagnostics Revenue in 2023
3.5 COVID-19 In-Vitro Diagnostics Key Players Head office and Area Served
3.6 Key Players COVID-19 In-Vitro Diagnostics Product Solution and Service
3.7 Date of Enter into COVID-19 In-Vitro Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 In-Vitro Diagnostics Breakdown Data by Type
4.1 Global COVID-19 In-Vitro Diagnostics Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global COVID-19 In-Vitro Diagnostics Forecasted 麻豆原创 Size by Type (2025-2030)
5 COVID-19 In-Vitro Diagnostics Breakdown Data by Application
5.1 Global COVID-19 In-Vitro Diagnostics Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global COVID-19 In-Vitro Diagnostics Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America COVID-19 In-Vitro Diagnostics 麻豆原创 Size (2019-2030)
6.2 North America COVID-19 In-Vitro Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2019-2024)
6.4 North America COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 In-Vitro Diagnostics 麻豆原创 Size (2019-2030)
7.2 Europe COVID-19 In-Vitro Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2019-2024)
7.4 Europe COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 In-Vitro Diagnostics 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific COVID-19 In-Vitro Diagnostics 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 In-Vitro Diagnostics 麻豆原创 Size (2019-2030)
9.2 Latin America COVID-19 In-Vitro Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2019-2024)
9.4 Latin America COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 In-Vitro Diagnostics 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa COVID-19 In-Vitro Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa COVID-19 In-Vitro Diagnostics 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cellex
11.1.1 Cellex Company Detail
11.1.2 Cellex Business Overview
11.1.3 Cellex COVID-19 In-Vitro Diagnostics Introduction
11.1.4 Cellex Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.1.5 Cellex Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott COVID-19 In-Vitro Diagnostics Introduction
11.2.4 Abbott Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.2.5 Abbott Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche COVID-19 In-Vitro Diagnostics Introduction
11.3.4 Roche Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.3.5 Roche Recent Development
11.4 BioMedomics
11.4.1 BioMedomics Company Detail
11.4.2 BioMedomics Business Overview
11.4.3 BioMedomics COVID-19 In-Vitro Diagnostics Introduction
11.4.4 BioMedomics Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.4.5 BioMedomics Recent Development
11.5 BD
11.5.1 BD Company Detail
11.5.2 BD Business Overview
11.5.3 BD COVID-19 In-Vitro Diagnostics Introduction
11.5.4 BD Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.5.5 BD Recent Development
11.6 Henry Schein
11.6.1 Henry Schein Company Detail
11.6.2 Henry Schein Business Overview
11.6.3 Henry Schein COVID-19 In-Vitro Diagnostics Introduction
11.6.4 Henry Schein Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.6.5 Henry Schein Recent Development
11.7 Safecare Bio-Tech
11.7.1 Safecare Bio-Tech Company Detail
11.7.2 Safecare Bio-Tech Business Overview
11.7.3 Safecare Bio-Tech COVID-19 In-Vitro Diagnostics Introduction
11.7.4 Safecare Bio-Tech Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.7.5 Safecare Bio-Tech Recent Development
11.8 Mayo Clinic Laboratories
11.8.1 Mayo Clinic Laboratories Company Detail
11.8.2 Mayo Clinic Laboratories Business Overview
11.8.3 Mayo Clinic Laboratories COVID-19 In-Vitro Diagnostics Introduction
11.8.4 Mayo Clinic Laboratories Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.8.5 Mayo Clinic Laboratories Recent Development
11.9 Chembio Diagnostics
11.9.1 Chembio Diagnostics Company Detail
11.9.2 Chembio Diagnostics Business Overview
11.9.3 Chembio Diagnostics COVID-19 In-Vitro Diagnostics Introduction
11.9.4 Chembio Diagnostics Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.9.5 Chembio Diagnostics Recent Development
11.10 Mount Sinai Laboratory
11.10.1 Mount Sinai Laboratory Company Detail
11.10.2 Mount Sinai Laboratory Business Overview
11.10.3 Mount Sinai Laboratory COVID-19 In-Vitro Diagnostics Introduction
11.10.4 Mount Sinai Laboratory Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.10.5 Mount Sinai Laboratory Recent Development
11.11 Ortho Clinical Diagnostics
11.11.1 Ortho Clinical Diagnostics Company Detail
11.11.2 Ortho Clinical Diagnostics Business Overview
11.11.3 Ortho Clinical Diagnostics COVID-19 In-Vitro Diagnostics Introduction
11.11.4 Ortho Clinical Diagnostics Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.11.5 Ortho Clinical Diagnostics Recent Development
11.12 Zhejiang Orient Gene Biotech
11.12.1 Zhejiang Orient Gene Biotech Company Detail
11.12.2 Zhejiang Orient Gene Biotech Business Overview
11.12.3 Zhejiang Orient Gene Biotech COVID-19 In-Vitro Diagnostics Introduction
11.12.4 Zhejiang Orient Gene Biotech Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.12.5 Zhejiang Orient Gene Biotech Recent Development
11.13 Innovita Biological Technology
11.13.1 Innovita Biological Technology Company Detail
11.13.2 Innovita Biological Technology Business Overview
11.13.3 Innovita Biological Technology COVID-19 In-Vitro Diagnostics Introduction
11.13.4 Innovita Biological Technology Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.13.5 Innovita Biological Technology Recent Development
11.14 Guangzhou Wondfo Biotech
11.14.1 Guangzhou Wondfo Biotech Company Detail
11.14.2 Guangzhou Wondfo Biotech Business Overview
11.14.3 Guangzhou Wondfo Biotech COVID-19 In-Vitro Diagnostics Introduction
11.14.4 Guangzhou Wondfo Biotech Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.14.5 Guangzhou Wondfo Biotech Recent Development
11.15 Guangdong Hecin-Scientific
11.15.1 Guangdong Hecin-Scientific Company Detail
11.15.2 Guangdong Hecin-Scientific Business Overview
11.15.3 Guangdong Hecin-Scientific COVID-19 In-Vitro Diagnostics Introduction
11.15.4 Guangdong Hecin-Scientific Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.15.5 Guangdong Hecin-Scientific Recent Development
11.16 Dynamiker Biotechnology (Tianjin)
11.16.1 Dynamiker Biotechnology (Tianjin) Company Detail
11.16.2 Dynamiker Biotechnology (Tianjin) Business Overview
11.16.3 Dynamiker Biotechnology (Tianjin) COVID-19 In-Vitro Diagnostics Introduction
11.16.4 Dynamiker Biotechnology (Tianjin) Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.16.5 Dynamiker Biotechnology (Tianjin) Recent Development
11.17 ADVAITE
11.17.1 ADVAITE Company Detail
11.17.2 ADVAITE Business Overview
11.17.3 ADVAITE COVID-19 In-Vitro Diagnostics Introduction
11.17.4 ADVAITE Revenue in COVID-19 In-Vitro Diagnostics Business (2019-2024)
11.17.5 ADVAITE Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Cellex
Abbott
Roche
BioMedomics
BD
Henry Schein
Safecare Bio-Tech
Mayo Clinic Laboratories
Chembio Diagnostics
Mount Sinai Laboratory
Ortho Clinical Diagnostics
Zhejiang Orient Gene Biotech
Innovita Biological Technology
Guangzhou Wondfo Biotech
Guangdong Hecin-Scientific
Dynamiker Biotechnology (Tianjin)
ADVAITE
听
听
*If Applicable.
